Brodalumab (Siliq) with a fatal touch: New psoriasis drug approved

Last Updated on

February 16, 2017 – The American Food & Drug Administration (FDA) just approved Brodalumab (Siliq) to treat adults with moderate-to-severe plaque psoriasis. Brodalumab (Siliq) is administered as an injection. Brodalumab (Siliq) is intended for patients who are candidates for systemic therapy (treatment using substances that travel through the bloodstream, after being taken by mouth or injected) or phototherapy (ultraviolet light treatment) and have failed to respond, or have stopped responding to other systemic therapies.

Psoriasis is a skin condition that causes patches of skin redness and flaking. Psoriasis is an autoimmune disorder that occurs more commonly in patients with a family history of the disease, and most often begins in people between the ages of 15 and 35. The most common form of psoriasis is plaque psoriasis, in which patients develop thick, red skin with flaky, silver-white scales. Siliq’s active ingredient (brodalumab) binds to a protein that causes inflammation, inhibiting the inflammatory response that plays a role in the development of plaque psoriasis.

Brodalumab (Siliq) efficacy was established in three randomized, placebo-controlled clinical trials with a total of 4,373 adult participants with moderate-to-severe plaque psoriasis who were candidates for systemic therapy or phototherapy. More patients treated with Brodalumab (Siliq) compared to placebo had skin that was clear or almost clear, as assessed by scoring of the extent, nature and severity of psoriatic changes of the skin.

However, when looking at its safety, suicidal ideation and behavior, including completed suicides, have occurred in patients treated with Brodalumab (Siliq) during clinical trials. Brodalumab (Siliq) users with a history of suicidality or depression had an increased incidence of suicidal ideation and behavior compared to users without this history. Here, the agency claims (or perhaps, even more plausible, the applicant for market authorisation) that a causal association between treatment with Brodalumab (Siliq) and increased risk of suicidal ideation and behavior has not been established. This may be true in  the strict sense that a molecular mechanism for Brodalumab (Siliq)-inducing directly completed suicide is not established. However, if already in a carefully preselected patient population of 4’373 participants in clinical trials, suicidal ideation occurs and completed suicides have occurred, there can be no question based of epidemiological evidence that Brodalumab (Siliq) causes suicidal ideation and completed suicides in that this two clinical phenotypes are much much more rare in both the general population and in the psoriasis patient population. In addition to these serious/fatal adverse effects of Brodalumab (Siliq), the most common adverse reactions reported with the use of Brodalumab (Siliq) included joint pain (arthralgia), headache, fatigue, diarrhea, throat pain (oropharyngeal pain), nausea, muscle pain (myalgia), injection site reactions, influenza, low white blood cell count (neutropenia) and fungal (tinea) infections.

Because of the observed risk of suicidal ideation and behavior, the labeling for Brodalumab (Siliq) includes a Boxed Warning and the drug is only available through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the Brodalumab (Siliq) REMS Program. Notable requirements of the Brodalumab (Siliq) REMS Program include the following:

  • Prescribers must be certified with the program and counsel patients about this risk. Patients with new or worsening symptoms of depression or suicidality should be referred to a mental health professional, as appropriate.
  • Patients must sign a Patient-Prescriber Agreement Form and be made aware of the need to seek medical attention should they experience new or worsening suicidal thoughts or behavior, feelings of depression, anxiety or other mood changes.
  • Pharmacies must be certified with the program and must only dispense to patients who are authorized to receive Brodalumab (Siliq).

Brodalumab (Siliq) is also approved with a Medication Guide to inform patients of the risk of suicidal ideation and behavior, and that because Brodalumab (Siliq) is a medication that affects the immune system, patients may have a greater risk of getting an infection, or an allergic or autoimmune condition. Patients with Crohn’s disease should not use Brodalumab (Siliq). Health care providers should also evaluate patients for tuberculosis (TB) infection prior to initiating treatment with Brodalumab (Siliq). Health care providers should not administer Brodalumab (Siliq) to patients with active TB infection, and should avoid immunizations with live vaccines in patients being treated with Brodalumab (Siliq).

Overall, in this particular case, one has really to question the risk/benefit ratio that has led FDA to approve Brodalumab (Siliq) in the first place, at how the agency could probably put so many psoriasis patient at a fatal risk? There is no antidote for completed suicide, remember.

 

Tags: , , , , , , , ,
About the Author
Joseph Gut - thasso Ph.D.; Professor in Pharmacology and Toxicology. Senior expert in theragenomic and personalized medicine and individualized drug safety. Senior expert in pharmaco- and toxicogenetics. Senior expert in human safety of drugs, chemicals, environmental pollutants, and dietary ingredients.

Your opinion

Comment

@peepso_user_30549(sajibuni)
Hello Everyone out there,I am here to give my testimony about a Herbalist doctor who helped me . I was infected with HERPES SIMPLEX VIRUS five years ago, i went to many hospitals for cure but there was no solution, so I was thinking how can I get a solution out so that my body can be okay. One day I was in the river side thinking where I can go to get solution. so a lady walked to me telling me why am I so sad and i open up all to her telling her my problem, she told me that she can help me out, she introduce me to a doctor who uses herbal medication to cure HERPES SIMPLEX VIRUS and gave me his email, so i mail him. He told me all the things I need to do and also give me instructions to take, which I followed properly. Before I knew what is happening after two weeks the HERPES SIMPLEX VIRUS that was in my body got vanished . so if you are also heart broken and also need a help, you can also email him at dr.chalaherbalhome@gmail.com or Contact him today on whatsapp number… Read more
3 weeks ago 3 weeks ago

thasso: conditions

thasso: tweets

thasso post: magazine

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

  • Mayo researchers recommend all women with breast cancer diagnosis under age 66 be offered genetic testing February 21, 2020
    A study by researchers at Mayo Clinic published this week in the Journal of Clinical Oncology suggests that all women with a breast cancer diagnosis under the age of 66 be offered germline genetic testing to determine if they have a gene mutation known to increase the risk of developing other cancers and cancers among […]
  • Cross-talk between enzymes that read and correct recipes in the cookbook of life February 21, 2020
    DNA is the hereditary material in humans, a unique cookbook of who we are. This is where you'll find the answer as to why you have your specific eye and hair colour, or perhaps why you sunburn easily.
  • Study finds certain genetic tests not useful in predicting heart disease risk February 21, 2020
    A Polygenic Risk Score—a genetic assessment that doctors have hoped could predict coronary heart disease (CHD) in patients—has been found not to be a useful predictive biomarker for disease risk, according to a Vanderbilt study published in the Journal of the American Medical Association.
  • Major discovery in the genetics of Down syndrome February 21, 2020
    Researchers at CHU Sainte-Justine and Université de Montréal have discovered a new mechanism involved in the expression of Down syndrome, one of the main causes of intellectual disability and congenital heart defects in children. The study's findings were published today in Current Biology.
  • MicroRNA exhibit unexpected function in driving cancer February 20, 2020
    Researchers long thought that only one strand of a double-stranded microRNA can silence genes. Though recent evidence has challenged that dogma, it's unclear what the other strand does, and how the two may be involved in cancer. New research from Thomas Jefferson University has revealed that both strands of some microRNA coordinate to act on […]
  • Specific gut bacteria may be associated with pulmonary arterial hypertension February 24, 2020
    Researchers have found a specific bacterial profile in the gut of people with pulmonary arterial hypertension, a chronic and progressive disease that causes constriction of arteries in the lungs. The unique bacterial profile predicted pulmonary arterial hypertension with 83% accuracy.
  • Intensive behavioral therapy and liraglutide 3.0 mg show positive results for weight loss February 24, 2020
    Intensive behavioral therapy (IBT) combined with liraglutide 3.0 mg (Saxenda) can produce clinically-meaningful weight loss in patients who receive the treatment in predominantly primary care settings, according to a study published online in Obesity, the flagship journal of The Obesity Society. The study is the first multi-site evaluation of the efficacy of IBT based on […]
  • Study links physical activity to quality of life in African American cancer survivors February 24, 2020
    New research published in CANCER suggests that regular exercise may improve the well-being of African American cancer survivors, but most survivors do not meet current recommendations for physical activity.
  • Obesity embargo alert for March 2020 February 24, 2020
    All print, broadcast and online journalists who receive the Obesity embargo alert agree to abide by the embargo and may not publish, post, broadcast or distribute embargoed news releases or details of the embargoed studies before the embargo date and time.
  • Could this plaque identifying toothpaste prevent a heart attack or stroke? February 24, 2020
    For decades, researchers have suggested a link between oral health and inflammatory diseases affecting the entire body -- in particular, heart attacks and strokes. Results of a randomized pilot trial of Plaque HD®, the first toothpaste that identifies plaque so that it can be removed with directed brushing, showed that it produced a statistically significant […]
Top